CompletedPhase 2NCT01554514
Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura
Studying Congenital thrombotic thrombocytopenic purpura
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Washington University School of Medicine
- Principal Investigator
- Elaine M Majerus, MD, PhDWashington University School of Medicine
- Intervention
- rituximab(biological)
- Enrollment
- 19 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2020
Study locations (4)
- Emory University, Atlanta, Georgia, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Washington University, St Louis, Missouri, United States
- Duke University Medical Center, Durham, North Carolina, United States
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01554514 on ClinicalTrials.govOther trials for Congenital thrombotic thrombocytopenic purpura
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07513948Daratumumab in Immune-mediated Thrombotic Thrombocytopenic PurpuraFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- RECRUITINGNCT06441578A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic PurpuraTakeda
- RECRUITINGNCT01257269Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)Insel Gruppe AG, University Hospital Bern
See all trials for Congenital thrombotic thrombocytopenic purpura →